Patents Assigned to Exonate Limited
  • 1-methyl-1H-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases
    Patent number: 12024504
    Abstract: Anti-angiogenic treatments and compounds for use in anti-angiogenic treatments, particularly of conditions associated with abnormal angiogenesis or abnormal over-production of pro-angiogenic VEGFxxx isoforms in or on the eye are described.
    Type: Grant
    Filed: August 3, 2022
    Date of Patent: July 2, 2024
    Assignee: EXONATE LIMITED
    Inventors: Andrew Douglas Baxter, Jonathan Morris
  • SRPK1 inhibitors
    Patent number: 11420969
    Abstract: Anti-angiogenic treatments, for example treatment of ocular neovascularization or cancer, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of treating or preventing fibrosis and compounds for use in such methods are described.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: August 23, 2022
    Assignee: Exonate Limited
    Inventors: Andrew Douglas Baxter, Jonathan Morris, Andrew David Morley
  • Compounds
    Patent number: 10696661
    Abstract: Anti-angiogenic treatments, for example treatment of ocular neovascularization or cancer, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of treating or preventing fibrosis and compounds for use in such methods are described.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: June 30, 2020
    Assignee: Exonate Limited
    Inventors: David Bates, Jonathan Morris, Hamish Toop, Jennifer Batson, Andrew David Morley